Precision BioSciences announced that its partner iECURE has received fast track designation from the FDA for ECUR-506. ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase, or OTC, deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences initiated with a Buy at Guggenheim
- Precision BioSciences Faces Partnership Termination, Eyes Future
- Precision announces return of programs, conclusion of collab with Prevail
- iECURE announces FDA clearance of IND application for ECUR-506
- Precision BioSciences price target raised to $30 from $2 at BTIG